B Cell/T Cell Interactions in Brucellosis

NIH RePORTER · NIH · R01 · $50,093 · view on reporter.nih.gov ↗

Abstract

Project Summary/Abstract In humans, Brucella spp. can cause a lifelong, debilitating disease, with relapses of undulating fever and other complications even with antibiotic treatment. No vaccines are currently licensed to prevent human brucellosis. In this focused Supplement, we will employ the BSL3 cell sorting capability of the University of Missouri Regional Biocontainment Laboratory (MURBL) along with RNA-seq to perform detailed transcriptional analyses of B and T cells in our model of vaccine-mediated immunity to Brucella. Our findings from this Supplement will complement the results from our parental proposal and provide us additional information which will enhance our understanding of how B cell antigen presentation inhibits vaccine-mediated immunity against Brucella, which in turn could improve the rational design of vaccines for brucellosis.

Key facts

NIH application ID
10630491
Project number
3R01AI150797-02S1
Recipient
UNIVERSITY OF MISSOURI-COLUMBIA
Principal Investigator
Jerod Skyberg
Activity code
R01
Funding institute
NIH
Fiscal year
2022
Award amount
$50,093
Award type
3
Project period
2020-11-18 → 2023-10-31